Cardinal Health, Inc. CAH reported third-quarter fiscal 2024 adjusted earnings per share (EPS) of $2.08, which beat the Zacks Consensus Estimate of $1.95 by 6.7%. The bottom line also improved 20% year over year. GAAP EPS in the quarter was $1.05 compared with $1.34 in the year-ago period. Revenue Details Sales improved 9% on a year-over-year basis to $54.9 billion. However, the top line missed the Zacks Consensus Estimate by 1.6%. Segmental Analysis Pharmaceutical and Specialty Solutions Segment In the reported quarter, pharmaceutical revenues increased 9% to $50.7 billion on a year-over-year basis. The performance highlights branded pharmaceutical sales growth from existing Pharmaceutical Distribution and Specialty Solutions customers. Pharmaceutical profit totaled $580 million, up 4% from the year-ago quarter’s level. The upside was driven by generics program performance. Global Medical Products and Distribution Segment Revenues in this segment totaled $3.1 billion, up 4% year over year, driven by growth volume from existing customers. The segment reported a profit of $20 million against a loss of $46 million in the year-ago quarter. This upside was driven by an improvement in net inflationary impacts, including mitigation initiatives. Other This segment includes three operating segments: at-Home Solutions, Nuclear and Precision Health Solutions and OptiFreight Logistics. Sales totaled $1.2 billion in the quarter, up 14% year over year. The segment’s profit amounted to $111 million, up 5% from the year-ago quarter’s level. The upside was driven by robust performance in OptiFreight Logistics. Cardinal Health, Inc. Price, Consensus and EPS Surprise Cardinal Health, Inc. Price, Consensus and EPS Surprise Cardinal Health, Inc. price-consensus-eps-surprise-chart | Cardinal Health, Inc. Quote Margin Analysis Gross profit increased 9.1% year over year to $1.95 billion. As a percentage of revenues, the gross margin in the reported quarter was 3.5%, almost flat on a year-over-year basis. Distribution, selling, general and administrative expenses totaled $1.28 billion, up 8.7% year over year. Operating income amounted to $367 million compared with $572 million in the year-ago quarter. However, adjusted operating income increased 10% year over year to $666 million. Financial Update The company exited the reported quarter with cash and cash equivalents of $3.72 billion compared with $4.59 billion in the fiscal second quarter of 2024. Cumulative net cash used in operating activities totaled $49 million against cumulative net cash provided by operating activities of $1.36 billion in the year-ago period. 2024 EPS View Raised Cardinal Health raised its fiscal 2024 guidance for earnings. The company now anticipates adjusted EPS between $7.30 and $7.40, up from the previous guidance of $7.20-$7.35. The Zacks Consensus Estimate for the same is pegged at $7.28. The company continues to expect revenues from its Pharmaceutical segment to grow 10-12%. Segmental profit is likely to increase 8.5-9.5%, up from the previous guidance of 7-9%. Revenues from the Medical segment are estimated to grow 2%. Segmental profit is expected to be $65 million in the quarter. The company also provided a preliminary guidance for fiscal 2025. It expects adjusted EPS to be at least $7.50 for the period. Segmental profit is estimated to grow at least 1% in the Pharmaceutical and Specialty Solutions segment and nearly $175 million in the Global Medical Products and Distribution segment. This metric for the Other segment is likely to grow nearly 10%. Conclusion Cardinal Health exited the fiscal third quarter on a mixed note. While its earnings beat the Zacks Consensus Estimate, revenues missed the same. However, the company witnessed year-over-year revenue growth across all its sectors. Shares of the company were down 1.4% in pre-market trading following mixed results. The company’s shares have risen 11% year to date compared with the industry’s growth of 7.3%. The broader S&P 500 Index has moved up 10.1% in the same period. Zacks Investment Research Image Source: Zacks Investment Research An intense competition and customer concentration are concerning. Zacks Rank and Stocks to Consider Cardinal Health carries a Zacks Rank #3 (Hold) at present. Some better-ranked stocks in the broader medical space that have announced quarterly results are Align Technology, Inc. ALGN, Ecolab ECL and Boston Scientific Corporation BSX. Align Technology, carrying a Zacks Rank of 2 (Buy) at present, reported first-quarter 2024 adjusted earnings per share (EPS) of $2.14, which beat the Zacks Consensus Estimate by 8.1%. Revenues of $997.4 million outpaced the consensus mark by 2.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Align Technology has a long-term estimated growth rate of 6.9%. ALGN’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 5.9%. Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. ECL’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 1.7%. Ecolab’s shares have rallied 33.8% against the industry’s 9.3% decline in the past year. Boston Scientific reported first-quarter 2024 adjusted EPS of 56 cents, which beat the Zacks Consensus Estimate by 9.8%. Revenues of $3.86 billion surpassed the Zacks Consensus Estimate by 4.9%. It currently carries a Zacks Rank #2. Boston Scientific has a long-term estimated growth rate of 12.5%. BSX’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.5%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX):Free Stock Analysis Report Ecolab Inc. (ECL):Free Stock Analysis Report Align Technology, Inc. (ALGN):Free Stock Analysis Report Cardinal Health, Inc. (CAH):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Cardinal Health (CAH) Beats on Q3 Earnings, Ups '24 EPS View
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...